---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-005595"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:46:19.577236+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode raises $7.25M in public offering; expects to regain Nasdaq equity compliance

## Summary
- Priced public offering of 5,942,623 shares (or pre-funded warrants) and warrants for 11,885,246 shares at $1.22/unit.
- Gross proceeds of $7.25M; net proceeds for clinical trials of TTX-MC138 and working capital.
- Offering closed Jan 22, 2024; warrants exercisable at $1.22, expire in 3.5 years.
- Company believes stockholders' equity now above $2.5M; Nasdaq compliance plan submitted and under review.
- H.C. Wainwright acted as placement agent; received agent warrants for 356,557 shares at $1.525.

## SEC filing metadata
- accession: 0001104659-24-005595
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/0001104659-24-005595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/tm243790d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-005595
- JSON: https://secwatch.observer/filing/0001104659-24-005595.json
- Plain text: https://secwatch.observer/filing/0001104659-24-005595.txt

## Key facts
- Material Agreements
  Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at approximately $7.25 million (effective 2024-01-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: approximately $7.25 million
  - Effective: 2024-01-18
  source text: On January 18, 2024, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/0001104659-24-005595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.